Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

SARS Covid virus

The ‘G2P-UK’ National Virology Consortium* will study how mutations in the virus affect key outcomes such as:

  • how transmissible it is
  • the severity of COVID-19 it causes
  • the effectiveness of vaccines and treatments.

The Fodor Lab (Sir William Dunn School of Pathology) and the Grimes Lab (Nuffield Department of Medicine) are pleased to be part of this project through their collaboration on the SARS-CoV-2 RNA polymerase. Specifically, they will be addressing how emerging mutations in the SARS-CoV-2 replicase genes affect the ability of the virus to replicate its RNA genome and, in collaboration with the other partners in the consortium, how these changes impact the properties of the virus, such as transmissibility, severity of the disease it causes and the immune responses it triggers.

The full story is available on the UKRI website

Similar stories

Nigeria rolls out new Oxford R21 malaria vaccine

On Thursday, Nigeria announced the regulatory approval and launch of the new R21/Matrix-M™ malaria vaccine that will be freely administered to recipients. This marks a significant milestone in the country’s fight against the deadly disease.